EXDENSUR DIN 02568934
Status: Marketed
Holder: GLAXOSMITHKLINE INC
Health Canada record
| Active ingredient(s) | DEPEMOKIMAB 100 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | R03DX12 DEPEMOKIMAB |
|---|
| Original market date | 17-Jul-2026 |
|---|
| Current status date | 17-Jul-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DEPEMOKIMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02568926 | EXDENSUR | GLAXOSMITHKLINE INC | Solution | DEPEMOKIMAB 100 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 37709 | 2026-06-15 | New Drug Submission (NDS) | |
Request a quote for EXDENSUR
How to read a Canadian DIN record